OBJECTIVE: Sustained excess BMI increases the risk of type 1 diabetes (T1D) in autoantibody-positive relatives without diabetes of patients. We tested whether elevated BMI also accelerates the progression of islet autoimmunity before T1D diagnosis. RESEARCH DESIGN AND METHODS: We studied 706 single autoantibody-positive pediatric TrialNet participants (ages 1.6-18.6 years at baseline). Cumulative excess BMI (ceBMI) was calculated for each participant based on longitudinally accumulated BMI ≥85th age- and sex-adjusted percentile. Recursive partitioning analysis and multivariable modeling defined the age cut point differentiating the risk for progression to multiple positive autoantibodies. RESULTS: At baseline, 175 children (25%) had a BMI ≥85th percentile. ceBMI range was -9.2 to 15.6 kg/m2 (median -1.91), with ceBMI ≥0 kg/m2 corresponding to persistently elevated BMI ≥85th percentile. Younger age increased the progression to multiple autoantibodies, with age cutoff of 9 years defined by recursive partitioning analysis. Although ceBMI was not significantly associated with progression from single to multiple autoantibodies overall, there was an interaction with ceBMI ≥0 kg/m2, age, and HLA (P = 0.009). Among children ≥9 years old without HLA DR3-DQ2 and DR4-DQ8, ceBMI ≥0 kg/m2 increased the rate of progression from single to multiple positive autoantibodies (hazard ratio 7.32, P = 0.004) and conferred a risk similar to that in those with T1D-associated HLA haplotypes. In participants <9 years old, the effect of ceBMI on progression to multiple autoantibodies was not significant regardless of HLA type. CONCLUSIONS: These data support that elevated BMI may exacerbate islet autoimmunity prior to clinical T1D, particularly in children with lower risk based on age and HLA. Interventions to maintain normal BMI may prevent or delay the progression of islet autoimmunity.
OBJECTIVE: Sustained excess BMI increases the risk of type 1 diabetes (T1D) in autoantibody-positive relatives without diabetes of patients. We tested whether elevated BMI also accelerates the progression of islet autoimmunity before T1D diagnosis. RESEARCH DESIGN AND METHODS: We studied 706 single autoantibody-positive pediatric TrialNet participants (ages 1.6-18.6 years at baseline). Cumulative excess BMI (ceBMI) was calculated for each participant based on longitudinally accumulated BMI ≥85th age- and sex-adjusted percentile. Recursive partitioning analysis and multivariable modeling defined the age cut point differentiating the risk for progression to multiple positive autoantibodies. RESULTS: At baseline, 175 children (25%) had a BMI ≥85th percentile. ceBMI range was -9.2 to 15.6 kg/m2 (median -1.91), with ceBMI ≥0 kg/m2 corresponding to persistently elevated BMI ≥85th percentile. Younger age increased the progression to multiple autoantibodies, with age cutoff of 9 years defined by recursive partitioning analysis. Although ceBMI was not significantly associated with progression from single to multiple autoantibodies overall, there was an interaction with ceBMI ≥0 kg/m2, age, and HLA (P = 0.009). Among children ≥9 years old without HLA DR3-DQ2 and DR4-DQ8, ceBMI ≥0 kg/m2 increased the rate of progression from single to multiple positive autoantibodies (hazard ratio 7.32, P = 0.004) and conferred a risk similar to that in those with T1D-associated HLA haplotypes. In participants <9 years old, the effect of ceBMI on progression to multiple autoantibodies was not significant regardless of HLA type. CONCLUSIONS: These data support that elevated BMI may exacerbate islet autoimmunity prior to clinical T1D, particularly in children with lower risk based on age and HLA. Interventions to maintain normal BMI may prevent or delay the progression of islet autoimmunity.
Authors: Christine T Ferrara; Susan M Geyer; Carmella Evans-Molina; Ingrid M Libman; Dorothy J Becker; John M Wentworth; Antoinette Moran; Stephen E Gitelman; Maria J Redondo Journal: J Clin Endocrinol Metab Date: 2017-12-01 Impact factor: 5.958
Authors: Danielle R Bouchard; Bianca Porneala; Ian Janssen; Marie-France Langlois; Jean-Patrice Baillargeon; Caroline S Fox; James B Meigs; Ralph B D'Agostino; Michael Pencina; Marie-France Hivert Journal: J Diabetes Complications Date: 2013-01-10 Impact factor: 2.852
Authors: Anette G Ziegler; Marian Rewers; Olli Simell; Tuula Simell; Johanna Lempainen; Andrea Steck; Christiane Winkler; Jorma Ilonen; Riitta Veijola; Mikael Knip; Ezio Bonifacio; George S Eisenbarth Journal: JAMA Date: 2013-06-19 Impact factor: 56.272
Authors: Christine Therese Ferrara; Susan Michelle Geyer; Yuk-Fun Liu; Carmella Evans-Molina; Ingrid M Libman; Rachel Besser; Dorothy J Becker; Henry Rodriguez; Antoinette Moran; Stephen E Gitelman; Maria J Redondo Journal: Diabetes Care Date: 2017-02-15 Impact factor: 19.112
Authors: Jean M Lawrence; Giuseppina Imperatore; Dana Dabelea; Elizabeth J Mayer-Davis; Barbara Linder; Sharon Saydah; Georgeanna J Klingensmith; Lawrence Dolan; Debra A Standiford; Catherine Pihoker; David J Pettitt; Jennifer W Talton; Joan Thomas; Ronny A Bell; Ralph B D'Agostino Journal: Diabetes Date: 2014-06-04 Impact factor: 9.461
Authors: Thomas F Dejgaard; Bernt J von Scholten; Erik Christiansen; Frederik F Kreiner; Lars Bardtrum; Matthias von Herrath; Chantal Mathieu; Sten Madsbad Journal: Diabetes Obes Metab Date: 2021-09-28 Impact factor: 6.408
Authors: Tom G Richardson; Daniel J M Crouch; Grace M Power; Fernanda Morales-Berstein; Emma Hazelwood; Si Fang; Yoonsu Cho; Jamie R J Inshaw; Catherine C Robertson; Carlo Sidore; Francesco Cucca; Steven S Rich; John A Todd; George Davey Smith Journal: Nat Commun Date: 2022-04-28 Impact factor: 17.694
Authors: William T Cefalu; Dana K Andersen; Guillermo Arreaza-Rubín; Christopher L Pin; Sheryl Sato; C Bruce Verchere; Minna Woo; Norman D Rosenblum Journal: Diabetes Care Date: 2022-01-01 Impact factor: 17.152
Authors: Maria J Redondo; Brandon M Nathan; Laura M Jacobsen; Emily Sims; Laura E Bocchino; Alberto Pugliese; Desmond A Schatz; Mark A Atkinson; Jay Skyler; Jerry Palmer; Susan Geyer; Jay M Sosenko Journal: Diabetologia Date: 2021-01-26 Impact factor: 10.122
Authors: Anita M Nucci; Suvi M Virtanen; David Cuthbertson; Johnny Ludvigsson; Ulle Einberg; Celine Huot; Luis Castano; Bärbel Aschemeier; Dorothy J Becker; Mikael Knip; Jeffrey P Krischer Journal: Diabetologia Date: 2021-01-21 Impact factor: 10.122